RAYMOND SAULS: Open Payments
NPI 1063461408 · LANCASTER, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,347 in 71 payments from 14 companies in 2025. Trend: 2023 $1,531 · 2024 $1,375 · 2025 $1,347
Food & beverage: $1,347
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 15 | $388 |
| PFIZER INC. | 21 | $343 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $145 |
| Lilly USA, LLC | 4 | $94 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $76 |
| Novo Nordisk Inc | 4 | $64 |
| Phathom Pharmaceuticals, Inc. | 3 | $57 |
| GlaxoSmithKline, LLC. | 2 | $49 |
| Astellas Pharma US Inc | 2 | $36 |
| Viatris Specialty LLC | 2 | $31 |
Products named: NURTEC ODT, FARXIGA, CAPLYTA, AIRSUPRA, ELIQUIS, MOUNJARO, VOQUEZNA, TRELEGY ELLIPTA.
Industry payments across MA — which companies pay providers there.
